Androgenic Alopecia Therapeutics Pipeline Analysis 2017

Androgenic Alopecia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other

Published: November 2017
Report Code: LS11169
Available Format:
Pages: 112

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation


Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both Donthe sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and toxins. In men, hair loss occurs in a well-defined pattern, beginning from above the temples and over a period, the hairline recedes to form a characteristic "M" shape. The pattern of hair loss in women differs from male-pattern baldness. The distinctive feature of androgenic alopecia is progressive and gradual miniaturization of hair follicles, accompanied by progressive decrease in the duration of anagen, and reduction of anagen to telogen ratio.



Many pharmaceutical companies are actively involved in drug discovery process using novel targets, for the treatment of androgenic alopecia. Aclaris Therapeutics, Inc. updated its pipeline by adding a Pre-Clinical drug candidate namely, topical Janus Kinase (JAK) inhibitors drug candidate, for the treatment of men suffering from androgenic alopecia. However, the pipeline contains proportion of products from established drug classes, with improved dosing regimens and administration routes compared with currently marketed products.

Pipeline Analysis

The androgenic alopecia therapeutics pipeline comprises approximately 24 drug candidates, in different stages of development.

Competitive Landscape

Some of the key players developing drugs for the treatment of androgenic alopecia therapeutics include GlaxoSmithKline plc, Almirall S.A., Allergan plc, RepliCel Life Sciences Inc. and others.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry